Profound Medical Corp.
NASDAQ:PROFMedical - Devices
+$0.27 today
- Market cap
- $253.09M
- Beta
- 0.52
- P/E (TTM)
- -6.3
- EPS (TTM)
- -$1.07
Volume 0.08M
Average 0.12M
PROF Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Profound Medical Corp.NASDAQ: PROF
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 17.4% from a year ago
Total equity stood at $59.62M at the end of Q1 FY2026, up 17.4% from a year earlier and down 34.5% from the prior quarter. Over 3 fiscal years it compounded at +20.5% a year.
Context
- Total equity amounted to 80.9% of total assets at the end of Q1 FY2026, down 2.6 pp from a year earlier.
- Total equity increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +17.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 90.99M USD
- Year-over-year change
- +50.6%
- 4-year CAGR
- +3.1%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.99M | +50.6% |
| FY2024 | 2024-12-31 | 60.42M | +93.5% |
| FY2023 | 2023-12-31 | 31.22M | -40.0% |
| FY2022 | 2022-12-31 | 52M | -35.4% |
| FY2021 | 2021-12-31 | 80.51M | — |
Total Equity vs competitors
How PROF compares with its peers on the latest reported figures
- PROF's Mar 2026 total equity of $59.62M is the 6th highest of the 11 companies compared; the peer median is $78.43M.
- Its year-over-year change of +17.4% is the 6th highest of 11, against a peer median of +3.1%.
- Total equity amounts to 80.9% of total assets for PROF, versus a peer median of 76.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $347.44M | +22.1% | +55.9% | 84.6% | |
AVRAnteris Technologies Global Corp. | Mar 2026 | $278.41M | +545.8% | — | 94.5% |
| Mar 2026 | $167.89M | -15.8% | -12.3% | 86.3% | |
| Dec 2025 | $139.73M | -26.1% | -13.6% | 86.2% | |
| Mar 2026 | $121.02M | -24.9% | -10.5% | 69.0% | |
| Mar 2026 | $59.62M | +17.4% | +20.5% | 80.9% | |
| Mar 2026 | $35.85M | +398.7% | — | 41.3% | |
| Mar 2026 | $24.57M | +211.0% | — | 37.1% | |
| Mar 2026 | $17.06M | -56.8% | -22.8% | 13.6% | |
| Mar 2026 | $12.81M | +137.3% | — | 18.0% | |
| Mar 2026 | -$311.59M | -479.3% | — | 446.4% | |
| Peer median (excluding PROF) | $78.43M | +3.1% | -12.3% | 76.8% | |
Competitors are the stored peer set for PROF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 67.06M | 46.52M | 26.21M | 54.91M | 81.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 1.41M | 6.34M | 7.29M | 7.05M | 9.86M |
| Inventory | 7.4M | 7.94M | 6.99M | 5.8M | 11.28M |
| Other Current Assets | 1.15M | 0 | 0 | 0 | 1.27M |
| Total Current Assets | 77.02M | 62.02M | 41.9M | 69.07M | 104.21M |
| Property, Plant & Equipment (Net) | 1.9M | 1.72M | 1.57M | 821.01K | 225K |
| Goodwill | 2.69M | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.43M | 680K | 490K | 261K | 138K |
| Long-term Investments | 3.62M | 0 | 0 | 0 | 410.89K |
| Tax Assets | 0 | 0 | 0 | 87K | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 87.96M |
| Total Non-current Assets | 9.64M | 2.4M | 2.06M | 1.17M | 88.73M |
| Total Assets | 86.66M | 64.42M | 43.96M | 70.23M | 192.94M |
| Account Payables | 3.18M | 2.03M | 865K | 1.32M | 2.14M |
| Short-term Debt | 249.66K | 523K | 2.1M | 1.74M | 291.73K |
| Tax Payables | 0 | 298K | 0 | 0 | 0 |
| Deferred Revenue | 476.35K | 471K | 721K | 419K | 0 |
| Other Current Liabilities | 247.66K | 621K | 1.42M | 1.03M | 5.83M |
| Total Current Liabilities | 4.15M | 4.19M | 6.37M | 6.57M | 8.32M |
| Long-term Debt | 0 | 6.65M | 5M | 2.92M | 6.16M |
| Deferred Tax Liabilities | 0 | 0 | 59K | 0 | 86.83M |
| Deferred Revenue (Non-current) | 873.82K | 764K | 728K | 49K | 531.42K |
| Other Non-current Liabilities | 0 | 0 | 73K | 71K | 108.2K |
| Total Non-current Liabilities | 2M | 8.23M | 6.36M | 3.25M | 93.63M |
| Total Liabilities | 6.15M | 12.42M | 12.73M | 9.81M | 101.95M |
| Common Stock | 219.28M | 205.83M | 222.21M | 281.55M | 443.54M |
| Retained Earnings | (160.48M) | (189.36M) | (217.35M) | (245.17M) | (394.1M) |
| Accumulated OCI | 4.74M | 16.84M | 5.57M | 2.74M | 6.88M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.51M | 52M | 31.22M | 60.42M | 90.99M |
| Total Debt | 1.38M | 8.23M | 7.87M | 5.12M | 6.45M |
| Net Debt | (65.69M) | (38.29M) | (18.35M) | (49.79M) | (75.34M) |
Profound Medical Corp.
NASDAQ:PROF
Intrinsic Alpha fair value
Locked
Current Price
$6.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.